Structured Formula For Losartan (Losartan Potassium Cadila For Zydus 1)
Losartan Potassium Tablet, Film Coated
Product Images NDC 0615-7960
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 0615-7960). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Ncs Healthcare Of Ky, Llc Dba Vangard Labs, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Structured Formula For Losartan (Losartan Potassium Cadila For Zydus 2)
The text provides data on a clinical study involving Atenolol and Losartan Potassium as treatment options. The study analyzed the adjusted risk reduction for the primary endpoint and found that 9% of patients experienced improvement. The adjusted risk reduction for Losartan Potassium was 13%, with a p-value of 0.021. The text also displays a chart showing the study month and the number of participants at each month.*
Structured Formula For Losartan (Losartan Potassium Cadila For Zydus 3)
Structured Formula For Losartan (Losartan Potassium Cadila For Zydus 4)
Structure Product Formula For Losartan (Losartan Potassium Cadila For Zydus 5)
This text provides information on the effects of Losartan Potassium tablets compared to a placebo in reducing the risk of ventricular tachycardia (VT) events in patients. The text indicates that Losartan Potassium tablets resulted in a 16.1% risk reduction compared to the placebo. The p-value for this result was 0.022. The text also displays a table with percentages corresponding to time intervals of 12, 24, and 48. It is unclear what these percentages represent, but it is possible that they are related to the incidence of VT events over time.*
Losartan Potassium 25mg Bingo Card Label (Losartan Potassium Cadila For Zydus 6)
This is a package label for Losartan Potassium Tabs USP 50mg manufactured by Cadila for Zydus. The lot number is 7959 and the expiry date is not specified. The package contains 30 tablets and is stored at temperatures between 20°- 25°C (68° 77° F). The package should be protected from light and dispensed in a tight, light-resistant container. Dosage information can be found on the package insert or label. The rest of the text includes various lot numbers and expiration dates for the same product.*
Losartan Potassium Tabs 50mg Bingo Card Label (Losartan Potassium Cadila For Zydus 7)
The text seems to be a collection of codes, markings, and labels related to Losartan Potassium tablets with a strength of 50 mg manufactured by Vanguard Labs in Glasgow KY 42141. The tablets come in packs of tens, and the labeling includes various lot numbers and expiration dates. It also mentions the NDC number and storage instructions. However, there is no other useful information available.*
Losartan Potassium 50mg Tabs Unit Dose Label (Losartan Potassium Cadila For Zydus 8)
This is a label of Losartan Potassium Tabs with lot number 7958, having the strength of 25 mg. The medication should be stored at a temperature of 20-25°C (68-77°F), and kept away from light. The packaging has been done by Vangard, Glasgow. The label highlights that the medicine should only be used for institutional use, and users should refer to the package insert or label for dosage instructions. Few other lot numbers for Losartan Potassium tabs and their manufacturing details have also been mentioned. There is no other pertinent information available from this label.*
Losartan Potassium Tabs Usp 100mg Bingo Label (Losartan Potassium Cadila For Zydus 9)
This is a medication package containing Losartan Potassium tabs USP 100 mg, manufactured by Cadila for Zydus. The package includes the lot number, expiration date, Rx-only, and NDC information. The medication should be stored at controlled room temperature and should be kept in a tight, light-resistant container to protect from light. The package insert or label should be referred for proper dosage information. The package also includes the trademark of Omnicare, Inc. This is for institutional use only.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
